Atezolizumab/hyaluronidase, sold under the brand name Tecentriq Hybreza, is a fixed-dose combination medication used for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.[1][2] It contains atezolizumab, a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody; and hyaluronidase (human recombinant), an endoglycosidase.[1] It is taken by subcutaneous injection.[1]
| Combination of | |
|---|---|
| Atezolizumab | Monoclonal antibody |
| Hyaluronidase | Endoglycosidase |
| Clinical data | |
| Trade names | Tecentriq Hybreza |
| License data | |
| Routes of administration | Subcutaneous |
| ATC code |
|
| Legal status | |
| Legal status | |
The most common adverse reactions include fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite.[1][2]
Atezolizumab/hyaluronidase was approved for medical use in the United States in September 2024.[1][2][3][4]
Medical uses
editAtezolizumab/hyaluronidase is a subcutaneous injection version of atezolizumab for all the adult indications as the intravenous formulation of atezolizumab including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.[2]
History
editThe subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy.[2] A total of 371 participants were randomized (2:1) to receive subcutaneous atezolizumab and hyaluronidase or intravenous atezolizumab until disease progression or unacceptable toxicity.[2]
References
edit- ^ a b c d e f "Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use" (PDF). Genentech, Inc. 2024. Archived (PDF) from the original on 13 September 2024. Retrieved 14 September 2024.
- ^ a b c d e f "FDA approves atezolizumab and hyaluronidase-tqjs". U.S. Food and Drug Administration. 12 September 2024. Archived from the original on 14 September 2024. Retrieved 14 September 2024.
This article incorporates text from this source, which is in the public domain.}
- ^ "FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy". Genentech (Press release). 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024.
- ^ "Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With Enhanze for Multiple Types of Cancer" (Press release). Halozyme Therapeutics. 12 September 2024. Archived from the original on 13 September 2024. Retrieved 14 September 2024 – via PR Newswire.
External links
edit- Clinical trial number NCT03735121 for "A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer" at ClinicalTrials.gov
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |